Mga Batayang Estadistika
| LEI | 549300QRKP1JTNHD2366 |
| CIK | 1488039 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Atossa Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2025 |
Exhibit 99.1 Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa’s Monotherapy at 3-weeks SEATTLE, August 12, 2025 — Atossa Therapeut |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 13, 2025 |
Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 7, 2025 |
FORM 8-K Item 8.01 Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 As filed with the Securities and Exchange Commission on March 26, 2025 Registration No. |
|
| March 26, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Atossa Therapeutics, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.18 par value 457(a) 12,000,000 $0.725(2) $8,700,000(2) $153.10 per $1,0 |
|
| March 25, 2025 |
EX-99.1 2 atos-ex991.htm EX-99.1 Exhibit 99.1 Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2025 |
Exhibit 21.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number: 001-3 |
|
| March 25, 2025 |
Exhibit 19.1 ATOSSA THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Atossa Therapeutics, Inc. (the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Poli |
|
| March 25, 2025 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the authorized capital stock of Atossa Therapeutics, Inc. (the “Company” or “we” or “our”). The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by |
|
| March 12, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 12, 2025 |
Exhibit 99.1 Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications SEATTLE, March 11, 2025 – Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategi |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 4, 2025 |
Exhibit 99.1 Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 SEATTLE, January 30, 2025 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the |
|
| December 10, 2024 |
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium SEATTLE, December 10, 2024 - Atossa Therapeutics, Inc. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 19, 2024 |
Up to $100,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279367 PROSPECTUS SUPPLEMENT Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC (“Jefferies” or the “Sales Agent”) relating to shares of our common stock, $0.18 par value per share. Under this prospectus supplement and the accompanying prospectus, and in accordance wit |
|
| November 19, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 19, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM November 19, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 12, 2024 |
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factor • Released a preliminary analysis from I-SPY 2 Endocrine Optimiza |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2024 |
Exhibit 99.1 Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, November 4, 2024 - Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| August 12, 2024 |
Employment Agreement with Heather Rees Dated July 1, 2024 Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 1, 2024 (the “Effective Date”), by and between Atossa Therapeutics Inc. (the “Company”) and Heather Rees (“Executive”). WHEREAS, the Company wishes to employ Executive as the Chief Financial Officer of the Company and Executive wishes to work in such capacity; and WHEREAS, the Company and Execu |
|
| August 12, 2024 |
For the Three Months Ended June 30, Exhibit 99.1 Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update • Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual Meeting • Completed enrollment in 80mg PK Run-in Cohort for EVANGELINE trial • Completed P |
|
| July 2, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATOSSA THERAPEUTICS, INC. Atossa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: That the current name of the Corporation is Atossa Therapeutics, Inc., and the Corporation was originally incorporat |
|
| July 2, 2024 |
2020 Stock Incentive Plan, as Amended Exhibit 10.1 ATOSSA THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN (Most Recently Amended effective as of June 27, 2024) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key persons (including Con |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 21, 2024 |
107 Spring Street, Seattle, WA 98104 May 21, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 14, 2024 |
May 14, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2024 |
Exhibit 4.1 ATOSSA THERAPEUTICS, INC. Debt Securities Indenture Dated as of [ ] [ ]., as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314 |
|
| May 13, 2024 |
As filed with the Securities and Exchange Commission on May 13, 2024 Registration Statement No. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 13, 2024 |
Calculation of Filing Fee Tables Form S-3 (Form Type) Atossa Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| May 13, 2024 |
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks • Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) • Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024— Atossa T |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 2, 2024 |
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 • First patient dosed in new Phase 2 breast cancer prevention study • Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting • Ended 2023 with $88.5 million of |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number: 001-3 |
|
| April 1, 2024 |
Exhibit 21.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| April 1, 2024 |
Incentive Compensation Clawback Policy Exhibit 97.1 INCENTIVE COMPENSATION CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of Atossa Therapeutics, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any such |
|
| April 1, 2024 |
Employment Letter with Heather Rees Dated October 6, 2023 EXHIBIT 10.13 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. October 6, 2023 Heather Rees [*] *Delivered via email Dear Heather, A significant factor in our success at Atossa Therapeutics is our people and the effort and talent the |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 1, 2024 |
Employment Agreement with Greg Weaver Dated June 1, 2023 Exhibit 10.12 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of June 1, 2023 (the “Effective Date”), by and between Atossa Therapeutics Inc. (the “Company”) and Gregory Weaver (“Executive”). WHEREAS, the Company wishes to employ Executive as the Executive Vice President and Chief Financial Officer of the Company and Executive wishes to work in such capacity; an |
|
| April 1, 2024 |
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 • First patient dosed in new Phase 2 breast cancer prevention study • Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting • Ended 2023 with $88.5 million of |
|
| March 18, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 12, 2024 |
EXHIBIT 99.1 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors SEATTLE, March 12, 2024 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Te |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2024 Atossa Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35610 26-4753208 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 13, 2023 |
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update ● Achieved significant enrollment milestones in ongoing Phase 2 clinical trials ● Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS ● Ended third quarter 2023 with $94.0 million of cash and cash equivalents SEATTLE, November 13, 2023 (GLOBE N |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commis |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSS |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commiss |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2023 (October 2, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorp |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2023 (September 26, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 30, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer I |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissi |
|
| August 14, 2023 |
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update EXHIBIT 99.1 Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update ● Achieved significant enrollment milestones in three ongoing Phase 2 clinical trials ● Broadened patent protection for proprietary (Z)-endoxifen ● Strengthened management team with appointment of Greg Weaver as Chief Financial Officer ● Ended second quarter 2023 with $99.4 million of cas |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2023 (July 13, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporat |
|
| June 28, 2023 |
Atossa Therapeutics Announces $10M Stock Repurchase Program Exhibit 99.1 Atossa Therapeutics Announces $10M Stock Repurchase Program SEATTLE, June 27, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that its Board of Directors has approved a share repurchase pr |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2023 (June 27, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporat |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2023 (June 21, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporat |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2023 (May 26, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporatio |
|
| May 22, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2023 (May 17, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporatio |
|
| May 22, 2023 |
Letter from BDO USA LLP, dated May 22, 2023 Exhibit 16.1 May 22, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on May 17, 2023, to be filed by our former client, Atossa Therapeutics, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 15, 2023 |
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update ● Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patients ● Full enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023 ● Ended first quarter 2023 with $103.9 million of cash and cash equivalents and no deb |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 (May 4, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissio |
|
| April 26, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ATOSSA THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place m |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2023 (April 4, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporat |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi |
|
| March 22, 2023 |
EXHIBIT 99.1 Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ende |
|
| March 22, 2023 |
Form of Indemnification Agreement EXHIBIT 10.3 ATOSSA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made effective as of January 6, 2020 (the “Effective Date”) by and between Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company, which is organized under the General Corporation Law of the State of Delaware (“DGCL”), wishes |
|
| March 22, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 22, 2023 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissio |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number: 001-35610 ATOSSA THERAP |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 (March 10, 2023) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorpor |
|
| February 9, 2023 |
ATOS / Atossa Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Atossa Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 04962H506 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2022 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commiss |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| November 7, 2022 |
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update SEATTLE, November 7, 2022 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to d |
|
| October 7, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 7, 2022 (October 5, 2022) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorp |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2022 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2022 |
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update SEATTLE, August 8, 2022 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financ |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2022 (July 1, 2022) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporatio |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2022 (June 28, 2022) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporati |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2022 (June 1, 2022) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporatio |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 (May 13, 2022) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporatio |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2022 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2022 |
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 1, 2022 |
PRELIMINARY PROXY STATEMENT ? SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 28, 2022 |
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update SEATTLE, February 28, 2022 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number 001-35 |
|
| February 28, 2022 |
Exhibit 22.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2022 (February 24, 2022) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of in |
|
| February 14, 2022 |
ATOS / Atossa Therapeutics Inc / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 04962H506 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Num |
|
| February 9, 2022 |
ATOS / Atossa Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Atossa Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 04962H506 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| January 13, 2022 |
SC 13G/A 1 p22-0101sc13ga.htm ATOSSA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.18 (Title of Class of Securities) 04962H506 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 15, 2021 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commis |
|
| November 15, 2021 |
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update SEATTLE, November 15, 2021 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces fina |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2021 (October 6, 2021) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorp |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2021 (September 7, 2021) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of in |
|
| August 13, 2021 |
Exibit 99.1 Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting SEATTLE, August 13, 2021 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2021 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissi |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2021 (May 14, 2021) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporatio |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 14, 2021 |
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financia |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 27, 2021 |
VIA EDGAR April 27, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 21, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 21, 2021 Registration Statement No. |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 5, 2021 |
PRE 14A 1 atos20210330pre14a.htm FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number 001-35 |
|
| March 31, 2021 |
2020 Stock Incentive Plan, as amended Exhibit 99.1 ATOSSA THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN (Amended effective as of March 29, 2021) SECTION 1.GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key persons (including Consultants and p |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2021 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissio |
|
| March 31, 2021 |
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announced financial r |
|
| March 31, 2021 |
Exhibit 22.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| March 31, 2021 |
As filed with the Securities and Exchange Commission on March 31, 2021 As filed with the Securities and Exchange Commission on March 31, 2021 Registration No. |
|
| March 23, 2021 |
17,361,100 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-248555 PROSPECTUS SUPPLEMENT (To Prospectus dated September 10, 2020) 17,361,100 Shares of Common Stock We are offering 17,361,100 shares (the “shares”) of our common stock, par value $0.18 per share (the “common stock”) pursuant to this prospectus supplement and the accompanying prospectus. In a concurrent private placement, |
|
| March 23, 2021 |
Exhibit 1.2 March 22, 2021 Mr. Steven C. Quay Chief Executive Officer Atossa Therapeutics, Inc. 107 Spring Street Seattle, WA 98104 Dear Mr. Quay: This letter (the ?Agreement?) constitutes the agreement between Maxim Group LLC, a limited liability company formed under the laws of the State of New York (?Maxim? or the ?Placement Agent?) and Atossa Therapeutics, Inc., a company incorporated under th |
|
| March 23, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 23, 2021 (March 22, 2021) ATOSSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorpor |
|
| March 23, 2021 |
Current Report on Form 8-K, as Exhibit 1.1 Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 22, 2021, between Atossa Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and condition |
|
| March 23, 2021 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 23, 2021 |
Form of Lock-up and Voting Agreement dated March 22, 2021 Exhibit 1.3 LOCK-UP AND VOTING AGREEMENT This Lock-Up and Voting Agreement (this ?Lock-Up and Voting Agreement?) is being delivered to you in connection with that certain Share Purchase Agreement (the ?SPA?) by and between Atossa Therapeutics, Inc., a Delaware corporation (the ?Company?), and the person(s) or entity(ies) named on the signature pages hereto (collectively, the ?Holder?). Reference i |
|
| March 22, 2021 |
As filed with the Securities and Exchange Commission on March 22, 2021 Registration Statement No. |
|
| March 22, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 22, 2021 (March 22, 2021) ATOSSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorpor |
|
| February 4, 2021 |
ATOSSA THERAPEUTICS, INC. 10,500,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(2) File No. 333-252335 PROSPECTUS ATOSSA THERAPEUTICS, INC. 10,500,000 Shares Common Stock This prospectus covers the sale of an aggregate of 10,500,000 shares (the “shares”) of our common stock, $0.18 par value per share (the “common stock”), by the selling stockholders identified in this prospectus (collectively with any of the holder’s transferees |
|
| January 28, 2021 |
VIA EDGAR January 28, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| January 22, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on January 22, 2021 Registration Statement No. |
|
| January 15, 2021 |
CUSIP No: 04962H506 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Num |
|
| January 15, 2021 |
CUSIP No: 04962H506 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Numb |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Number) January 6, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 14, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.18 (Title of Class of Securities) 04962H506 (CUSIP Number) January 6, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 8, 2021 |
Securities Purchase Agreement dated January 6, 2021 Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2021, between Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| January 8, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 8, 2021 (January 6, 2021) ATOSSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorp |
|
| January 8, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-248555 PROSPECTUS SUPPLEMENT (To Prospectus dated September 10, 2020) Units consisting of an Aggregate of 23,850,000 Shares of Common Stock and Warrants Convertible Into 17,887,500 Shares of Common Stock (and the Shares of Common Stock Underlying the Warrants) We are offering units consisting of an aggregate of 23,850,000 shar |
|
| January 8, 2021 |
Exhibit 1.2 January 6, 2021 Mr. Steven C. Quay Chief Executive Officer Atossa Therapeutics, Inc. 107 Spring Street Seattle, WA 98104 Dear Mr. Quay: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC, a limited liability company formed under the laws of the State of New York (“Maxim” or the “Placement Agent”) and Atossa Therapeutics, Inc., a company incorporated under t |
|
| January 8, 2021 |
Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT ATOSSA THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [], 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Number) December 17, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 21, 2020 |
Exhibit 1.2 December 17, 2020 Mr. Steven C. Quay Chief Executive Officer Atossa Therapeutics, Inc. 107 Spring Street Seattle, WA 98104 Dear Mr. Quay: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC, a limited liability company formed under the laws of the State of New York (“Maxim” or the “Placement Agent”) and Atossa Therapeutics, Inc., a company incorporated under |
|
| December 21, 2020 |
Securities Purchase Agreement dated December 17, 2020 Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 17, 2020, between Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| December 21, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2020 (December 17, 2020) ATOSSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of in |
|
| December 21, 2020 |
Current Report on Form 8-K, as Exhibit 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 21, 2020 |
14,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-248555 PROSPECTUS SUPPLEMENT (To Prospectus dated September 10, 2020) 14,000,000 Shares of Common Stock We are offering 14,000,000 shares (the “shares”) of our common stock, par value $0.18 per share (the “common stock”) pursuant to this prospectus supplement and the accompanying prospectus. In a concurrent private placement, |
|
| December 18, 2020 |
CUSIP No: 04962H506 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Atossa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Numb |
|
| December 14, 2020 |
Exhibit 3.1 ATOSSA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Steven C. Quay and Kyle Guse, do hereby certify that: 1. They are the President and Secretary, respectively, of Atossa Therapeutics, Inc., a Delaware corporation (the “Corpora |
|
| December 14, 2020 |
Exhibit 1.1 14,575,000 SHARES of Common Stock, 5,425 SHARES OF SERIES C CONVERTIBLE PREFERRED STOCK, AND 15,000,000 WARRANTS (EXERCISABLE for 15,000,000 shares OF COMMON STOCK) OF Atossa Therapeutics, Inc. UNDERWRITING AGREEMENT December 8, 2020 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 405 Lexington Avenue, 2nd Floor New York, New York 1 |
|
| December 14, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2020 (December 8, 2020) ATOSSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of inc |
|
| December 14, 2020 |
Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT ATOSSA THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [], 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| December 11, 2020 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-250820 Units Consisting of an Aggregate of 14,575,000 Shares of Common Stock 5,425 Shares of Series C Convertible Preferred Stock and Warrants Convertible Into Up to 15,000,000 Shares of Common Stock (and the Shares of Common Stock Underlying the Preferred Stock and Warrants) Units consisting of an aggregate of 14,57 |
|
| December 8, 2020 |
Form of Series C Convertible Preferred Stock Exhibit 3.1 FORM OF ATOSSA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Steven C. Quay and Kyle Guse, do hereby certify that: 1. They are the President and Secretary, respectively, of Atossa Therapeutics, Inc., a Delaware corporation (the |
|
| December 8, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 8, 2020 (December 8, 2020) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of inco |
|
| December 8, 2020 |
Form of Warrant Agency Agreement Exhibit 4.2 ATOSSA THERAPEUTICS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent Form of Warrant Agency Agreement Dated as of , 2020 FORM OF WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2020 (“Agreement”), between Atossa Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and VStock Transfer, LLC., a limited lability company orga |
|
| December 8, 2020 |
Form of Common Stock Purchase Warrant Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT ATOSSA THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [], 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| December 7, 2020 |
VIA EDGAR December 7, 2020 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 7, 2020 |
VIA EDGAR December 7, 2020 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 1, 2020 |
Exhibit 4.9 FORM OF COMMON STOCK PURCHASE WARRANT ATOSSA THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [], 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| December 1, 2020 |
Exhibit 3.8 FORM OF ATOSSA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Steven C. Quay and Kyle Guse, do hereby certify that: 1. They are the President and Secretary, respectively, of Atossa Therapeutics, Inc., a Delaware corporation (the |
|
| December 1, 2020 |
Form of Underwriting Agreement Exhibit 1.1 [ ] SHARES of Common Stock, [ ] SHARES OF SERIES C CONVERTIBLE PREFERRED STOCK, AND [ ] WARRANTS (EXERCISABLE for [ ] shares OF COMMON STOCK) OF Atossa Therapeutics, Inc. UNDERWRITING AGREEMENT December [ ], 2020 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 405 Lexington Avenue, 2nd Floor New York, New York 10174 Ladies and Gentl |
|
| December 1, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on December 1, 2020 Registration No. |
|
| December 1, 2020 |
Form of 2020 Warrant Agency Agreement Exhibit 4.10 ATOSSA THERAPEUTICS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent Form of Warrant Agency Agreement Dated as of , 2020 FORM OF WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2020 (“Agreement”), between Atossa Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and VStock Transfer, LLC., a limited lability company org |
|
| November 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 26, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commis |
|
| November 20, 2020 |
Registration Statement - FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on November 20, 2020 Registration No. |
|
| November 13, 2020 |
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update SEATTLE, November 13, 2020 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today annou |
|
| November 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commis |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| September 25, 2020 |
Exhibit 1.1 ATOSSA THERAPEUTICS, INC. $10,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT September 25, 2020 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 Ladies and Gentlemen: Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Maxim Group LLC, as follows: 1. Issuance and Sale of Shares. The Company agrees that, from |
|
| September 25, 2020 |
ATOSSA THERAPEUTICS, INC. Up to $10,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-248555 PROSPECTUS SUPPLEMENT (To Prospectus dated September 10, 2020) ATOSSA THERAPEUTICS, INC. Up to $10,000,000 Common Stock We have entered into an Equity Distribution Agreement, dated September 25, 2020, or the Distribution Agreement, with Maxim Group LLC, or Maxim, relating to shares of our common stock, par value $0.18 per share, offered |
|
| September 25, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 25, 2020 (September 25, 2020) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of |
|
| September 8, 2020 |
September 8, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 2, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on September 2, 2020 Registration Statement No. |
|
| September 2, 2020 |
Exhibit 4.1 ATOSSA THERAPEUTICS, INC. Debt Securities Indenture Dated as of [ ] [ ]., as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314 |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissi |
|
| August 13, 2020 |
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update SEATTLE, August 13, 2020 (GLOBE NEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announ |
|
| May 19, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA THERAPEUTICS, INC. |
|
| May 13, 2020 |
Current Report on Form 10Q, as Exhibit 4.1 Exhibit 4.1 INCENTIVE STOCK OPTION AGREEMENT UNDER THE ATOSSA THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date (110% of FMV if a 10% owner)] Grant Date: Expiration Date: [up to 10 years (5 if a 10% owner)] Pursuant to the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan as amended through the date hereof ( |
|
| May 13, 2020 |
EX-99.1 2 ex182513.htm EXHIBIT 99.1 Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs SEATTLE, May 13, 2020 (GLOBENEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical |
|
| April 13, 2020 |
Current Report on Form 8-K, as Exhibit 4.1 Exhibit 4.1 STOCK OPTION AGREEMENT UNDER THE ATOSSA THERAPEUTICS, INC. 2020 STOCK INCENTIVE PLAN (Subject to Shareholder approval May 15, 2020) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Vesting Commencement Date: Grant Date: Expiration Date: Pursuant to the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan (the “Plan”), Atossa Therapeutics, Inc. (the “Company”) h |
|
| April 13, 2020 |
Atossa Therapeutics, Inc. 2020 Stock Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy State |
|
| April 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 9, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissio |
|
| March 26, 2020 |
Current Report on Form 10K, as exhibit 22.1 EX-22.1 3 ex167063.htm EXHIBIT 22.1 Exhibit 22.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| March 26, 2020 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.16 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Atossa Therapeutics, Inc. (the “Company” or “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): c |
|
| March 26, 2020 |
Exhibit 99.1 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update SEATTLE, March 26, 2020 (GLOBENEWSWIRE) - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the fourth |
|
| March 26, 2020 |
ATOS / Atossa Genetics Inc 10-K - Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number 001-35 |
|
| February 10, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2020 (February 7, 2020) Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of inco |
|
| February 10, 2020 |
Exhibit 1.1 ATOSSA THERAPEUTICS, INC. $5,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT February 7, 2020 Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, New York 10004 Ladies and Gentlemen: Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc., as follows: 1. Issuance and Sale of Shares. The Company |
|
| February 7, 2020 |
ATOSSA THERAPEUTICS, INC. Up to $5,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-220572 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2017) ATOSSA THERAPEUTICS, INC. Up to $5,000,000 Common Stock We have entered into an Equity Distribution Agreement, dated February 7, 2020, or the Distribution Agreement, with Oppenheimer & Co. Inc., or Oppenheimer, relating to shares of our common stock, par value $0.18 per share, o |
|
| January 7, 2020 |
Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATOSSA GENETICS INC. Atossa Genetics Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: That the Board of Directors of the Corporation has duly adopted resolutions authorizing the Corporation to execute and file wi |
|
| January 7, 2020 |
Amendment to Bylaws of Atossa Therapeutics, Inc. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ATOSSA THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place m |
|
| January 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2020 Atossa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2019 |
Exhibit 99.1 Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update Completes Third Quarter with Cash and Cash Equivalents of $15.3 Million SEATTLE, November 13, 2019 (GLOBENEWSWIRE) - Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditio |
|
| November 13, 2019 |
ATOS / Atossa Genetics Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA GENETICS INC. |
|
| October 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 14, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission F |
|
| August 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 13, 2019 |
Exhibit 99.1 Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update Completes Second Quarter with Cash and Cash Equivalents of $17.1 Million SEATTLE, August 13, 2019 (GLOBENEWSWIRE) - Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditio |
|
| August 13, 2019 |
ATOS / Atossa Genetics Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA GENETICS INC. |
|
| June 27, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission File |
|
| June 27, 2019 |
Exhibit 99.1 Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density SEATTLE, WA - (Marketwired) – June 27, 2019 - Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary analysis f |
|
| May 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission File |
|
| May 13, 2019 |
Exhibit 99.1 Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update Completes First Quarter with Cash and Cash Equivalents of $19.6 Million SEATTLE, May 13, 2019 (GLOBENEWSWIRE) - Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, to |
|
| May 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission File |
|
| May 13, 2019 |
ATOS / Atossa Genetics Inc 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA GENETICS INC. |
|
| April 12, 2019 |
ATOS / Atossa Genetics Inc FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy State |
|
| March 28, 2019 |
Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update Exhibit 99.1 Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update SEATTLE, March 28, 2019 (GLOBENEWSWIRE) - Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced year end 2018 financial results and provided an update on rec |
|
| March 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 28, 2019 |
Exhibit 22.1 LIST OF SUBSIDIARIES Atossa Genetics UK Ltd. Atossa Genetics AUS Pty Ltd. |
|
| March 28, 2019 |
ATOS / Atossa Genetics Inc FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from: to Commission File Number 001-35 |
|
| February 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Atossa Genetics Inc. (Name of Issuer) Common Stock, $0.18 par value per share (Title of Class of Securities) 04962H506 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 15, 2019 |
Current Report on Form 8-K, as Exhibit 4.1 Exhibit 4.1 STOCK OPTION AGREEMENT UNDER THE ATOSSA GENETICS INC. 2010 STOCK OPTION AND INCENTIVE PLAN (as amended January 13, 2019) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Vesting Commencement Date: Grant Date: Expiration Date: Pursuant to the Atossa Genetics Inc. 2010 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Atossa Genetics |
|
| January 15, 2019 |
8-K 1 atos201901158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2019 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdicti |
|
| January 15, 2019 |
2010 Stock Option and Incentive Plan, as amended January 13, 2019 Exhibit 4.2 ATOSSA GENETICS INC. 2010 STOCK OPTION AND INCENTIVE PLAN (as amended by the Board of Directors on January 13, 2019 (the “2019 Amendment”) subject to and conditioned upon stockholder approval) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Atossa Genetics Inc. 2010 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and |
|
| November 14, 2018 |
ATOS / Atossa Genetics Inc FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35610 ATOSSA GENETICS INC. |
|
| November 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2018 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2018 |
Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update Exhibit 99.1 Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update SEATTLE, November 13, 2018 - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced third quarter ended September 30, 2018 financial results and provide |
|
| November 13, 2018 |
ATOS / Atossa Genetics Inc FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| September 13, 2018 |
Exhibit 99.2 Preliminary Topical Endoxifen Male Phase 1 Results All Objectives Successfully Met September 13, 2018 1 107 Spring St. Seattle WA 98104 Forward - Looking Statements Some of the information presented herein may contain projections or other forward - looking statements regarding future events or the future financial performance of the Company which the Company undertakes no obligation t |
|
| September 13, 2018 |
Financial Statements and Exhibits, Other Events, Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 13, 2018 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission |
|
| September 13, 2018 |
Exhibit 99.1 Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen ***All Objectives Successfully Met*** Conference Call to Be Held Today at 10 am Eastern Time SEATTLE, Sept. 13, 2018 (GLOBE NEWSWIRE) - Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other br |
|
| August 13, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2018 Atossa Genetics Inc. (Exact name of registrant as specified in its charter) Delaware 001-35610 26-4753208 (State or other jurisdiction of incorporation) (Commission Fi |
